TD Cowen analyst Marc Frahm downgraded Blueprint Medicines (NASDAQ: BPMC) from Buy to Hold with a price target of $130.00.The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE